IMA203 (ACTengine®)
Recurrent/refractory solid tumors (melanoma, ovarian, HNSCC, uveal melanoma)
Key Facts
Indication
Recurrent/refractory solid tumors (melanoma, ovarian, HNSCC, uveal melanoma)
Phase
Phase 1b
Status
Active
Company
About Immatics
Immatics is dedicated to developing transformative T-cell receptor (TCR) therapies to address the significant unmet need in solid tumors. Its core strength lies in its proprietary discovery platforms that identify novel, cancer-specific targets presented by HLA molecules, enabling the development of highly specific TCR-based therapeutics. The company has established strategic partnerships with major players like Bristol Myers Squibb and has multiple clinical-stage assets, including TCR-T cell therapies and TCR Bispecifics, positioning it at the forefront of the next wave of immuno-oncology.
View full company profile